Stem cell therapy for type 1 DM.

2016-04-13T05:57:52Z (GMT) by Ahmed El-Badawy Nagwa El-Badri
<p>(A-C) Comparison of the outcome of different types of stem cells in T1DM by Intravenous administration of Umbilical Cord Blood (UCB, <i>n</i> = 61), Umbilical Cord-Mesenchymal Stem Cells (UC-MSCs, <i>n</i> = 15) and Bone Marrow Hematopoietic Stem Cells (BM-HSCs, <i>n</i> = 82) (D-E) Bar graphs depicting the change in C-peptide and HbA1c levels from baseline and 12 months after intravenous administration of different types of stem cells. (F-G) Line graphs showing changes in C-peptide and HbA1c levels over time at baseline, 3, 6 and 12 months after stem cell therapy in T1DM patients. All data are expressed as the mean ± SEM. **** P < 0.0001.</p>